Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial
- 1 April 2018
- journal article
- letter
- Published by Elsevier in Journal of Hepatology
- Vol. 68 (4) , 840-842
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyClinical Infectious Diseases, 2017
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus InfectionAnnals of Internal Medicine, 2017
- Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)Liver International, 2017
- Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialHepatology, 2016
- Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 InfectionAnnals of Internal Medicine, 2015
- Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 InfectionGastroenterology, 2015
- Modelling hepatitis C therapy—predicting effects of treatmentNature Reviews Gastroenterology & Hepatology, 2015
- Individualizing treatment duration in hepatitis C virus genotype 2/3‐infected patientsLiver International, 2010